Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SRK-181 + unspecified PD-L1 antibody |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SRK-181 | SRK 181|SRK181 | SRK-181 is TGFbeta1 (TGFB1) antibody, which potentially enhances anti-tumor immune response (PMID: 32213632). | ||
unspecified PD-L1 antibody | Experimental PD-L1 antibody | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04291079 | Phase I | SRK-181 + unspecified PD-L1 antibody SRK-181 SRK-181 + unspecified PD-1 antibody | SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | 1 |